Recruitment of participants for ivermectin trials starts in November -- DOST exec | Inquirer

Recruitment of participants for ivermectin trials starts in November — DOST exec

By: - Reporter /
/ 02:46 PM October 23, 2021

Ivermectin

FILE PHOTO: A box of the drug Ivermectin, made by Biogaran, is pictured on the counter of a pharmacy, as the spread of the coronavirus disease (COVID-19) continues, in Paris, France, April 28, 2020. REUTERS/Benoit Tessier

MANILA, Philippines — The recruitment of participants for the clinical trials on the use of ivermectin as COVID-19 treatment will start in November and the initial results may be out by the end of December, an official of the Department of Science and Technology (DOST) said Saturday.

According to DOST Undersecretary for Research and Development Rowena Cristina Guevara, pre-clinical trial activities for the ivermectin study are already ongoing.

Article continues after this advertisement

She said the identified study sites are the Ateneo Quarantine Facility, La Salle Quarantine Facility, University of the Philippines Diliman, and the Makati Science High School Quarantine Facility.

FEATURED STORIES

“Posible din na magrecruit tayo sa Region 2 at 11 kapag kinulang. Ang ating patient recruitment ay mag-uumpisa ngayong Nobyembre at ang release ng preliminary results ay sa end ng December 2021,” she said at the Laging Handa public briefing.

(We may recruit additional participants in Region 2 and 11. Patient recruitment will start this November and the release of preliminary results will be by the end of December.)

Article continues after this advertisement

Guevara noted that the UP Manila College of Pharmacy is formulating the ivermectin capsules to be used in the clinical trials.

Article continues after this advertisement

She said the study will assess the efficacy, safety, and effect on the viral clearance of ivermectin to asymptomatic and non-severe COVID-19 patients in the said isolation facilities.

Article continues after this advertisement

The government has allocated P22 million for the conduct of the study.

At present, ivermectin is only approved for human use as an anti-nematode drug. Health authorities have stressed that there is still no evidence that ivermectin can be a treatment for COVID-19.

/MUF
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the and acknowledge that I have read the .

For more news about the novel coronavirus click
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this

business
cebudailynews
globalnation
globalnation
globalnation
www
globalnation
globalnation
sports
www
TAGS: coronavirus Philippines, COVID-19, DOST, Ivermectin

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the and acknowledge that I have read the .

© Copyright 1997-2024 | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies.